SI-BONE INC
SIBNNASDAQTrading Snapshot
- Day Range
- $18.88 – $19.27
- 52-Week Range
- $11.48 – $21.89
- Volume
- $3.33B
- Avg Volume
- $2.67B
- Shares Outstanding
- 44.3M
- Next Earnings
- Nov 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $201M
- Last Q Revenue
- $56M
- P/E Ratio
- -55.2
- P/S Ratio
- 3.9x
- EPS (TTM)
- $-0.33
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3.6%
Why Investors Own SIBN
- ✓High-growth profile — revenue up -3.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 71% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SI-BONE INC
SIBN
StockOtter · stockotter.spaceAbout SI-BONE INC
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
SI-BONE INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift SIBN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
SI-BONE INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.